Prodrugs pp 1221-1229 | Cite as

Case Study: Enalapril: A Prodrug of Enalaprilat

  • Sundeep S. Dhareshwar
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)


Enalaprilat is a potent and reversible inhibitor of the plasma and tissue angiotensin-converting enzyme (ACE); it is used clinically in the treatment of hypertension (Patchett et al., 1980; Gross et al., 1981). Although enalaprilat has potent and prompt therapeutic activity when administered intravenously, its high polarity and transport characteristics cause it to be poorly absorbed from the gastrointestinal tract. This leads to extremely low bioavailability of enalaprilat when administered orally (Biollaz et al., 1982).


Angiotensin Convert Enzyme Angiotensin Convert Enzyme Inhibitor Carboxylate Moiety Enalapril Maleate Lysine Analogue 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abu-Zahra TN, Wolkoff AW, Kim RB, and Pang KS. Uptake of Enalapril and Expression of Organic Anion Transporting Polypeptide 1 in Zonal, Isolated Rat Hepatocytes. Drug Metab Dispos 2000; 28:801–806PubMedGoogle Scholar
  2. Biollaz J, Burnier M, Turini GA, Brunner DB, Porchet M, Gomez HJ, Jones KH, Ferber F, Abrams WB, Gavras H, and Brunner HR. Three New Long-Acting Converting Enzyme Inhibitors: Relationship between Plasma Converting Enzyme Activity and Response to Angiotensin-I. Clin Pharmacol Ther 1981; 29:665–670PubMedGoogle Scholar
  3. Biollaz J, Schelling JL, Jacot Des Combes B, Brunner DB, Desponds G, Brunner HR, Ulm EH, Hichens M, and Gomez HJ. Enalapril Maleate and a Lysine Analogue (MK-521) in Normal Volunteers; Relationship between Plasma Drug Levels and the Renin Angiotensin System. Br J Clin Pharmacol 1982; 14:363–368.PubMedGoogle Scholar
  4. Cressman MD, Vidt DG, and Acker C. Renal Glycosuria and Azotemia after Enalapril Maleate (MK-421). Lancet, Aug 21 1982; 2:440–442PubMedCrossRefGoogle Scholar
  5. Davies RO, Gomez HJ, Irvin JD, and Walker JF. An Overview of the Clinical Pharmacology of Enalapril. Br J. Clin Pharmacol 1984; 18Suppl 2:215S–229SPubMedGoogle Scholar
  6. Drummer OH, Nicolaci J, Iakovidis D. Biliary Excretion and Conjugation of Diacid Angiotensin Converting-Enzyme Inhibitors. J Pharmacol Exp Ther 1990; 252:1202–1206PubMedGoogle Scholar
  7. Eyjolfsson R. Formulations of Quinapril and Related ACE Inhibitors. European Patent #WO-030359388 (July 24) 2003Google Scholar
  8. Friedman DI, and Amidon, GL. Passive and Carrier-Mediated Intestinal Absorption Component of two Angiotensin Converting Enzyme (ACE) Inhibitor Prodrugs in Rats: Enalapril and Fosinopril. Pharm Res 1989; 6:1043–1047PubMedCrossRefGoogle Scholar
  9. Gross DM, Sweet CS, Ulm EH, Backlund EP, Morris AA, Weitz D, Bohn DL, Wenger HC, Vassil TC, and Stone CA. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its Ethyl Ester (MK-421) on Angiotensin Converting Enzyme in vitro and Angiotensin-I Pressor Responses in vivo. J Pharmacol Exp Ther 1981; 216:552–557.PubMedGoogle Scholar
  10. Irvin JD, Till AE, Vlasses PH, Hitchens M, Rotmensch HH, Harris KE, Merrill DD, and Ferguson RK. Bioavailability of Enalapril Maleate. Clin Pharmacol Ther 1984; 33: 248–256.Google Scholar
  11. Kelly JG, Doyle G, Donohue J, Laher M, Vandenburg MJ, Currie WJ, and Cooper WD. Pharmacokinetics of Enalapril in Normal Subjects and Patients with Renal Impairment. Br J Clin Pharmacol, 1986; 21:63–69PubMedGoogle Scholar
  12. Larmour I, Jackson B, Cubela R, and Johnston CI. Enalapril (MK 421) Activation in Man: Importance of Liver Status. Br J Clin Pharmacol, 1985; 19:701–704PubMedGoogle Scholar
  13. Lo M-W, McCrea JB, Shadle CR, Hesney M, Chiou R, Cylc D, Yuan AS; and Goldberg MR. Enalapril in RAPIDISC (wafer formulation): Pharmacokinetic Evaluation of a Novel, Convenient Formulation. Int J Clin Pharmacol Therap 2000; 38:327–33Google Scholar
  14. Pang KS, Barker F IIIrd, Cherry WF, and Goresky, CA. Esterases for Enalapril Hydrolysis Are Concentrated in the Perihepatic Venous Region of the Rat Liver. J Pharmacol. Exp Ther 1991; 257:294–301PubMedGoogle Scholar
  15. Patchett AA, Harris E, Tristram EW, Wyvratt MJ, Wu MT, Taub D, Peterson ER, Ikeler TJ, ten Broeke J, Payne LG, Ondeyka DL, Thorsett ED, Greenlee WJ, Lohr NS, Hoffsommer RD, Joshua H, Ruyle WV, Rothrock JW, Aster SD, Maycock AL, Robinson FM, Hirschmann R, Sweet CS, Ulm EH, Gross DM, Vassil TC, and Stone CA. A New Class of Angiotensin-Converting Enzyme Inhibitors. Nature 1980; 288:280–283PubMedCrossRefGoogle Scholar
  16. Sherman BC. Stable Solid Formulation of Enalapril Salt and Process for Preparation Thereof. US Patent #5573780 (August 4) 1995.Google Scholar
  17. Slater EE, Merrill DD, Guess HA, Roylance PJ, Cooper WD, Inman WH, and Ewan PW. Clinical Profile of Angioedema Associated with Angiotensin Converting Enzyme Inhibition. J Am Med Assoc., Aug 19 1988; 260: 967–970CrossRefGoogle Scholar
  18. Spireas S. Stable Formulations of ACE Inhibitors. US Patent #2003225124 (February 12) 2003Google Scholar
  19. Stofik S, Gwozdz R, Pelloni C, and James JC. Stable Formulations of Angiotensin Converting Enzyme (ACE) Inhibitors. US Patent #2003215526 (March 7) 2003Google Scholar
  20. Swaan PW, Stehouwer MC, and Tukker JJ. Molecular Mechanism for the Relative Binding Affinity to the Intestinal Peptide Carrier. Comparison of Three ACE-inhibitors: Enalapril, Enalaprilat, and Lisinopril. Biochim Biophys Acta 1995; 1236:31–38.PubMedCrossRefGoogle Scholar
  21. Swanson BN, Vlasses PH, Ferguson RK, Bergquist PA, Till AE, Irvin JD, and Harris K. Influence of Food on the Bioavailability of Enalapril. J Pharm Sci 1984; 73(11):1655–1657PubMedCrossRefGoogle Scholar
  22. Sweet CS, Gross DM, Arbegast PT, Gaul SL, Britt PM, Ludden CT, Weitz D, and Stone CA. Antihypertensive Activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), An Orally Active Converting Enzyme Inhibitor. J Pharmacol Exp Ther 1981; 216:558–566PubMedGoogle Scholar
  23. Tien M-J, and Liu Y-L. Method for Producing Angiotensin Converting Enzyme Inhibitor. US Patent #6,541,635 (April 1) 2003Google Scholar
  24. Till AE, Gomez HJ, Hichens M, Bolognese JA, McNabb WR, Brooks BA, Noormohamed F, and Lant AF. Pharmacokinetics of Repeated Single Oral Doses of Enalapril Maleate (MK-421) in Normal Volunteers. Biopharm Drug Dispos 1984; 5:273–280PubMedCrossRefGoogle Scholar
  25. Tocco DJ, deLuna FA, Duncan AEW, Vassil TC, and Ulm E H. The Physiological Disposition and Metabolism of Enalapril Maleate in Laboratory Animals. Drug Metab Dispos 1982; 10:15–19PubMedGoogle Scholar
  26. Ulm EH, Hichens M, Gomez HJ, Till AE, Hand E, Vassil TC, Biollaz J, Brunner HR, Schelling JL. Enalapril Maleate and a Lysine Analogue (MK-521): Disposition in Man. Br J Clin Pharmacol 1982; 14:357–362PubMedGoogle Scholar
  27. Ulm EH. Enalapril Maleate (MK-421), a Potent Nonsulfhydryl Angiotensin Converting Enzyme Inhibitor: Absorption, Disposition, and Metabolism in Man. Drug Metab Rev 1983; 14:99–110PubMedCrossRefGoogle Scholar
  28. Wyvratt MJ, Tristram EW, Ikeler TJ, Lohr NS, Joshua H, Springer JP, Arison, BH, and Patchett AA. Reductive Amination of Ethyl 2-oxo-4-phenylbutanoate with L-alanyl-L-proline. Synthesis of Enalapril Maleate. J Org Chem 1984; 49:2816–2819CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Sundeep S. Dhareshwar
    • 1
  1. 1.Department of Pharmaceutical ChemistryThe University of KansasLawrenceUSA

Personalised recommendations